PsyRx and NextGen have regulatory progress, but the value still depends on funding and clinical execution
PsyRx and NextGen reported useful regulatory and IP milestones, but the filings remain pre-clinical proof and pre-commercial proof. PsyRx improved the supply path for GMP ibogaine but shifted the human clinical request to the second half of 2026. NextGen received Helsinki approv…
